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Abstract
Background: Cardiorespiratory fitness (CRF) has a strong inverse relationship with 
several chronic disease outcomes, including some cancers. The association between 
CRF and prostate cancer is controversial. We aimed to assess the prospective as-
sociation of CRF with prostate cancer risk using a cohort study and review of the 
literature.
Material and methods: Cardiorespiratory fitness was assessed using a respiratory 
gas exchange analyser during exercise testing in 2204 cancer- free middle- aged men. 
Hazard ratios (HRs) with 95% confidence interval (CIs) were estimated. We cor-
rected for within- person variability in CRF levels using repeat measurements.
Results: During a median follow- up of 24.9 years, 216 prostate cancer cases oc-
curred. The age- adjusted regression dilution ratio of CRF was 0.58 (95% CI: 0.53- 
0.64). The HR (95% CI) of prostate cancer per 1 standard deviation increase in CRF 
in age- adjusted analysis was 1.10 (0.95- 1.27). The association remained consistent 
after further adjustment for several risk factors (HR 1.13; 95% CI 0.96- 1.33). The 
corresponding adjusted HRs were 1.24 (95% CI: 0.87- 1.77) and 1.28 (95% CI: 0.87- 
1.88), respectively, when comparing the extreme tertiles of CRF levels. Previous 
studies mostly reported no evidence of an association or an increased risk of prostate 
cancer in relation to high CRF. Studies reporting positive associations had short- term 
follow- up durations (<10 years).
Conclusions: Primary data and a review of previous studies suggest that elevated 
CRF is not associated with reduced prostate cancer risk. Previous findings of signifi-
cant evidence of associations could be attributed to increased screening and detection 
as well as reverse causation bias.
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1 |  INTRODUCTION
Cancer is a global health burden, being the leading cause of 
death worldwide at all income levels.1 With the ageing pop-
ulation and a steep increase in unfavourable lifestyle habits 
that predispose to cancer risk, the number of cancer cases 
and deaths attributed to these are expected to grow rapidly.1 
Prostate cancer is the second most frequently diagnosed can-
cer among males globally, and it is also one of the leading 
causes of death from cancer in men. It is commonly associ-
ated with factors such as race, age, family history, hereditary 
factors, infections, hormonal changes and those related to 
economic development such as excess body weight, physi-
cal inactivity and high consumption of animal fats.2- 6 Though 
these factors explain a large proportion of the risk of prostate 
cancer, it appears other potential risk factors may be involved, 
as its pathogenesis is still not fully established. Identification 
of other modifiable factors that may have causal or predictive 
significance will increase our knowledge of the aetiology of 
prostate cancer and help in the development of preventive and 
management strategies.
A wealth of epidemiologic evidence suggests that physi-
cal activity (PA) may protect against several chronic diseases 
including certain cancers.7 A protective association between 
physical activity and prostate cancer has also been reported.8 
Maximal oxygen uptake (VO2max), a cardiopulmonary ex-
ercise testing (CPX) parameter9,10 and commonly used as a 
measure of cardiorespiratory fitness (CRF), is an index of 
habitual physical activity.9 Like PA, CRF has also been con-
sistently shown to be independently and inversely associated 
with several chronic disease outcomes.11- 13 A number of ob-
servational cohort studies have investigated the associations 
of CRF with the specific outcome of prostate cancer, but their 
results have been inconsistent. Some studies have reported 
an increased risk of prostate cancer with high CRF,14- 17 
whereas others reported a decreased risk18 or no evidence of 
an association.19- 22 Notably, these previous studies employed 
indirect methods or nonexercise algorithms for estimating 
CRF rather than the gold standard measure, that is CPX 
with VO2max measured by ventilatory expired gas analysis.
23 
However, there are limitations associated with non- use of the 
gold standard measure, which include: (a) underestimation 
and overestimation of CRF at the top and bottom ends of 
the distribution, respectively,10 and (b) a particular equation 
may not be suitable for all populations.24 The availability of 
CRF, ascertained with the gold standard measure, within the 
Kuopio Ischaemic Heart Disease (KIHD) prospective study 
offered the opportunity to revaluate the nature and magnitude 
of the association between CRF and prostate cancer in greater 
detail than in previous studies. To put these findings into con-
text, we also reviewed the literature for previously published 
evidence on the associations between CRF and prostate can-
cer risk.
2 |  METHODS
2.1 | Study participants and assessment of 
covariates and outcomes
Reporting of the study conforms to broad EQUATOR 
guidelines25 and was conducted according to STROBE 
(STrengthening the Reporting of OBservational studies in 
Epidemiology) guidelines for reporting observational stud-
ies in epidemiology (Table  S1).26 The study population 
were participants in the KIHD risk factor study, a prospec-
tive population- based cohort study designed to investigate 
risk factors for vascular disease and other chronic outcomes. 
The cohort comprised of middle- aged men aged 42- 61 years 
who were recruited from Kuopio in eastern Finland. The 
study design and recruitment methods have been described 
in detail previously.27 Following exclusion of those who did 
not respond to the invitation and declined to give informed 
consent, the final cohort comprised of 2682 participants who 
had baseline measurements performed between March 1984 
and December 1989. The present analysis included a cohort 
of 2204 cancer- free men at baseline, with complete informa-
tion on CRF, relevant confounders and incident prostate can-
cer cases. The study was approved by the Research Ethics 
Committee of the University of Eastern Finland, and each 
participant provided written informed consent. All study 
procedures were conducted according to the Declaration of 
Helsinki. Maximal oxygen uptake was used as a measure of 
CRF and was measured using a respiratory gas exchange ana-
lyser during a maximal symptom- limited cycle ergometer ex-
ercise tolerance test.28 Repeat measurements of VO2max were 
performed 11 years after the baseline measurements, during 
the follow- up period in a random subset of participants. We 
included all incident cases of prostate cancer that occurred 
from study enrolment through 2014.29 Cases were derived 
from the population- based Finnish Cancer Registry (FCR). 
Every diagnosed cancer case in the healthcare system has 
been reported in a countrywide and population- based manner 
in Finland since 1953. The coverage of FCR is complete, and 
there were no losses to follow- up.30
2.2 | Statistical analysis
Baseline characteristics of participants were summarised using 
descriptive analyses. Hazard ratios (HRs) with 95% confidence 
intervals (CIs) were calculated using Cox proportional hazard 
models. Cardiorespiratory fitness was modelled as per 1 stand-
ard deviation (SD) increase and as tertiles. Hazard ratios were 
adjusted for age (Model 1) and for age, smoking status, history 
of type 2 diabetes, fasting plasma glucose (FPG), total choles-
terol, triglycerides, alcohol consumption, total energy intake, 
socioeconomic status (SES), total physical activity and high 
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sensitivity C- reactive protein (hsCRP) (Model 2). Because 
prostate cancer has a long latency period (subclinical phase), 
this could cause declines in levels of CRF long before definite 
diagnosis (ie, reverse causation bias). To account for this po-
tential bias, sensitivity analysis involved limiting analysis to 
participants with at least 10 years of follow- up. The 10- year 
threshold was chosen for consistency with previous studies re-
porting on outcomes with long latency periods19,31 Analyses 
restricted to the first 10 years of follow- up could not be con-
ducted due to a low number of events in this time window. Due 
to measurement errors in exposure estimation, ageing and life-
style changes in long- term prospective cohort studies, analysis 
using only baseline measurements of an exposure could under-
estimate the true strength of any association between exposure 
and outcome (ie, ‘regression dilution bias’32). To address this 
issue, we used repeat measurements of VO2max taken 11 years 
apart in a random subset of 551 men to correct for the effect 
of this regression dilution bias. This was achieved by estimat-
ing adjusted regression dilution ratios (RDRs), calculated by 
regressing available repeat measurements on baseline values33 
as reported in previous studies.34- 36 All statistical analyses were 
conducted using Stata version MP 16 (Stata Corp.).
2.3 | Literature review
A search was conducted in MEDLINE from inception to 13 
January 2021, to identify observational cohort studies (with at 
least one year of follow- up) that had evaluated the association 
between CRF and prostate cancer risk in general populations. 
The computer- based searches used a combination of keywords 
or terms relating to the exposure (‘cardiorespiratory fitness’, 
‘aerobic fitness’) and outcome (‘prostate cancer’). We did not 
conduct a meta- analysis as it would be inappropriate to do this, 
given the excessive variation in the assessment of CRF meas-
ures, follow- up periods and results. With regard to follow- up for 
cancer outcomes, combining findings from short- term follow-
 up studies and those of long- term follow- up studies will yield 
biased estimates, due to the long latency period for cancers.
3 |  RESULTS
3.1 | Observational cohort analysis
The mean (SD) of age and CRF of study participants at base-
line were 53 (5) years and 30.3 (8.0) mL/kg/min, respectively 
(Table 1). During a median (interquartile range) follow- up of 
24.9 (17.3- 27.0) years, 216 cases of prostate cancer occurred, 
corresponding to an annual rate of 4.54/1000 person- years at 
risk (95% CI: 3.98 to 5.19). The HR for prostate cancer per 
1 SD increase in CRF in analysis adjusted for age was 1.10 
(95% CI: 0.95- 1.27), which remained consistent in analyses 
additionally adjusted for several risk factors (smoking status, 
history of type 2 diabetes, FPG, total cholesterol, triglycer-
ides, alcohol consumption, total energy intake, SES, total 
physical activity and hsCRP) and 1.13 (95% CI: 0.96- 1.33) 
(Table 2). The corresponding adjusted HRs were 1.24 (95% 
CI: 0.87- 1.77) and 1.28 (95% CI: 0.87- 1.88), respectively, 
when comparing the top versus bottom tertiles of CRF lev-
els. The overall age- adjusted RDR of CRF was 0.58 (95% 
CI: 0.53- 0.64), which suggests that if there was a significant 
association between CRF and prostate CA, using one- off or 
baseline measurements of CRF could underestimate the risk 
by [(1/0.58) − 1] × 100 = 72%. The HRs were more extreme 
following correction for within- person variability in CRF 
levels (Table 2). In sensitivity analyses, results were consist-
ent in analyses limited to participants with at least 10 years of 
follow- up (Table S2).
3.2 | Literature review findings
We identified eight population- based prospective cohort 
studies reporting on the associations between CRF and 
prostate cancer risk, which were published from 1996 to 
T A B L E  1  Baseline participant characteristics
Mean (SD) or median 
(IQR) or n (%)
CRF (mL/(kg.min)) 30.3 (8.0)
Questionnaire/Prevalent conditions
Age at survey (years) 53 (5)
Alcohol consumption (g/week) 31.8 (6.4- 90.8)
Total energy intake, kJ/d 9655 (8148- 11 332)
Socioeconomic status 8.41 (4.23)
History of type 2 diabetes 76 (3.5)
Current smokers 683 (30.9)
Physical measurements
BMI (kg/m2) 26.9 (3.5)
SBP (mm Hg) 134 (17)
DBP (mm Hg) 89 (10)
Total physical activity (kcal/d) 1212 (637- 1990)
Blood- based biomarkers
Total cholesterol (mmol/L) 5.91 (1.07)
HDL- C (mmol/L) 1.29 (0.30)
Triglycerides (mmol/L) 1.09 (0.79- 1.53)
Fasting plasma glucose (mmol/L) 5.33 (1.21)
High sensitivity CRP (mg/L) 1.23 (0.69- 2.37)
Abbreviations: BMI, body mass index; CHD, coronary heart disease; CRP, 
C- reactive protein; DBP, diastolic blood pressure; HDL- C, high- density 
lipoprotein cholesterol; IQR, interquartile range; SBP, systolic blood pressure; 
SD, standard deviation.
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2020 (Table 3).14- 21 The average age at baseline ranged from 
approximately 18.0 to 59.2 years. Four studies were based 
in North America (USA) and four in Europe (Denmark, 
Norway, Sweden and UK). Average duration of follow- up 
ranged from 5.0 to 44 years. All studies employed indirect 
methods for the assessment of CRF, which were based on 
submaximal or maximal treadmill/bicycle exercise tests. 
Four studies with follow- up durations ranging from 5.0 to 
9.3 years reported an increased risk of prostate cancer with 
high CRF levels.14- 17 Three studies with follow- up dura-
tions ranging from 12.7 to 44.0 years reported no evidence 
of an association.19- 21 Only one study, which was published 





Model 1 Model 2
HR (95% CI) P- value HR (95% CI) P- value
Baseline CRF
Per 1 SD increase 216/2204 1.10 (0.95- 1.27) .19 1.13 (0.96- 1.33) .16
T1 (6.36- 26.87) 56/735 ref ref
T2 (26.88- 33.24) 79/735 1.25 (0.88- 1.77) .21 1.22 (0.86- 1.75) .26
T3 (33.25- 65.40) 81/734 1.24 (0.87- 1.77) .23 1.28 (0.87- 1.88) .22
Usual CRFa 
Per 1 SD increase 216/2204 1.18 (0.92- 1.52) .19 1.23 (0.93- 1.63) .16
T1 (6.36- 26.87) 56/735 ref ref
T2 (26.88- 33.24) 79/735 1.47 (0.81- 2.67) .21 1.42 (0.77- 2.62) .26
T3 (33.25- 65.40) 81/734 1.45 (0.79- 2.68) .23 1.52 (0.78- 2.97) .22
Note: Model 1: Adjusted for age. Model 2: Model 1 plus smoking status, history of type 2 diabetes, fasting 
plasma glucose, total cholesterol, triglycerides, alcohol consumption, total energy intake, socioeconomic 
status, total physical activity and high sensitivity C- reactive protein.
Abbreviations: CI, confidence interval; CRF, cardiorespiratory fitness; HR, hazard ratio; ref, reference; SD, 
standard deviation; T, tertile.
aIndicates correction for within- person variability in values of CRF, that is the extent to which an individual's 
CRF measurements vary around a long- term average value (‘usual CRF values’). 
T A B L E  2  Association between 
cardiorespiratory fitness and risk of prostate 
cancer
T A B L E  3  Baseline characteristics of published prospective cohort studies (1996- 2020)
Author, year of 




(yrs) CRF measure CRF assessment
No. of 
participants







Oliveria, 1996 Copper Clinic USA 1970- 1989 44.2 ~10.0 Treadmill time Maximal or symptom- limited 
treadmill exercise test




Byun, 2011 ACLS USA 1976- 2003 45.6 9.3 Maximal METs Symptom- limited exercise 
treadmill testing
19 042 634 High vs Low 1.74 
(1.15- 2.62)
Lakoski, 2015 CCLS USA 1971- 2009/1999- 2009 49.0 6.5 Peak METs Incremental treadmill test 
(indirect method)
13 949 1310 High vs Low 1.22 
(1.02- 1.46)
Jensen, 2017 Copenhagen Male 
Study
Denmark 1970- 1971 48.8 44.0 Maximal oxygen consumption 
(VO2max)
Bicycle ergometer test (indirect 
method)




Robsahm, 2017 Oslo Ischemia Study Norway 1972- 1975 49.8 26.2 Maximal aerobic workload Incremental bicycle exercise test 
(indirect method)
1997 213 High vs Low 1.20 
(0.83- 1.74)
Vainshelboim, 2017 VETS USA 1987- 2012 59.2 12.7 Peak METs Maximal treadmill exercise test 4920 337 High vs Low 0.97 
(0.68- 1.40)
Steell, 2019 UK Biobank UK 2007- 2010 40- 69a 5.0 Maximal METs Submaximal cycle ergometer test 73 259 — High vs Low 1.16 
(1.02- 1.32)
Crump, 2020 — Sweden 1972- 1985 18.0 — Maximal aerobic workload — 699 125 10 782 High vs Low 1.10 
(1.03- 1.19)
Abbreviations: ACLS, Aerobics Center Longitudinal Study; CCLS, Cooper Center Longitudinal Study; VETS, Veterans Exercise Testing Study.
aAge range; CA, cancer; CRF, cardiorespiratory fitness; MET, metabolic equivalent; NR, not reported; VO2max, maximal oxygen uptake. 
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4 |  DISCUSSION
In this new study which examines the prospective associa-
tion between objectively measured CRF and risk of prostate 
cancer in a general population- based cohort of middle- aged 
Caucasian men who were followed over two decades, the 
results did not suggest evidence of an association. Our re-
sults are in line with some earlier studies that have evaluated 
the association. Of the eight studies identified in the litera-
ture review, three of the studies which were all published in 
2017, involved middle- aged men and with average follow-
 up durations ranging from 12.7 to 44.0 years, demonstrated 
no evidence of an association between CRF and prostate 
cancer.19- 21 Contrary to these findings, the majority of previ-
ously published studies reported an increased risk of prostate 
cancer with high CRF levels.14- 17
A consistent relationship has been demonstrated between 
high CRF and lower risk of all- cause and some site- specific 
cancers.15,19,37 Chronic inflammation has been reported to 
play a major role in prostate carcinogenesis,4,38 and multi-
ple factors suggested to contribute to the chronic inflamma-
tion process include infections, dietary factors and hormonal 
changes.4 Increased testosterone levels and hyperglycaemia 
are also known to contribute to prostate carcinogenesis.39,40 
The protective effect of CRF on cancer may be attributed to 
the role of PA, which is well established to influence CRF 
levels.41 Regular PA may exert a protective effect on pros-
tate cancer via dampening of inflammatory responses, tu-
mour growth suppression, decrease in excessive levels of 
testosterone, increased insulin sensitivity and immunological 
mechanisms.42- 44 Given the evidence, it would seem our null 
findings are unexpected. However, the associations between 
CRF and some site- specific cancers have been especially 
strong and consistent for lung and colorectal cancers,15,37,45 
whereas findings for CRF and prostate CA risk have been 
inconsistent. More surprisingly, the majority of published 
studies have demonstrated evidence of an increased risk of 
prostate cancer with high CRF levels.14- 17 These findings 
have been attributed to increased healthcare awareness and 
screening and early detection (diagnostic bias).15,19 Jensen 
et al19 report that due to these factors, prostate cancer mortal-
ity may be a more sensitive outcome measure of the associa-
tion between CRF and prostate cancer. This is consistent with 
the fact that CRF is strongly and inversely associated with 
all- cause mortality.46 In addition to factors above, evidence of 
associations demonstrated by previous studies may have been 
influenced by reverse causation bias, as many cancers (in-
cluding prostate cancer) have a long subclinical development 
which may cause PA and CRF to decline in the early stages of 
follow- up. Consistent with this hypothesis, significant find-
ings have been demonstrated predominantly in studies with 
short- term follow- up durations (average of 5- 10 years),14- 17 
with no evidence of associations for long- term follow- up 
studies.19- 21 The null association observed between CRF 
and prostate cancer may reflect important differences be-
tween CRF and the aetiopathogenesis of prostate cancer 
and other site- specific cancers such as lung and colorectal 
cancers. Hence, it is possible that the lack of an association 
between CRF and prostate CA may actually be a true associ-
ation. In a recent comprehensive review of 48 cohort and 24 
T A B L E  3  Baseline characteristics of published prospective cohort studies (1996- 2020)
Author, year of 




(yrs) CRF measure CRF assessment
No. of 
participants







Oliveria, 1996 Copper Clinic USA 1970- 1989 44.2 ~10.0 Treadmill time Maximal or symptom- limited 
treadmill exercise test




Byun, 2011 ACLS USA 1976- 2003 45.6 9.3 Maximal METs Symptom- limited exercise 
treadmill testing
19 042 634 High vs Low 1.74 
(1.15- 2.62)
Lakoski, 2015 CCLS USA 1971- 2009/1999- 2009 49.0 6.5 Peak METs Incremental treadmill test 
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13 949 1310 High vs Low 1.22 
(1.02- 1.46)
Jensen, 2017 Copenhagen Male 
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Denmark 1970- 1971 48.8 44.0 Maximal oxygen consumption 
(VO2max)
Bicycle ergometer test (indirect 
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Robsahm, 2017 Oslo Ischemia Study Norway 1972- 1975 49.8 26.2 Maximal aerobic workload Incremental bicycle exercise test 
(indirect method)
1997 213 High vs Low 1.20 
(0.83- 1.74)
Vainshelboim, 2017 VETS USA 1987- 2012 59.2 12.7 Peak METs Maximal treadmill exercise test 4920 337 High vs Low 0.97 
(0.68- 1.40)
Steell, 2019 UK Biobank UK 2007- 2010 40- 69a 5.0 Maximal METs Submaximal cycle ergometer test 73 259 — High vs Low 1.16 
(1.02- 1.32)
Crump, 2020 — Sweden 1972- 1985 18.0 — Maximal aerobic workload — 699 125 10 782 High vs Low 1.10 
(1.03- 1.19)
Abbreviations: ACLS, Aerobics Center Longitudinal Study; CCLS, Cooper Center Longitudinal Study; VETS, Veterans Exercise Testing Study.
aAge range; CA, cancer; CRF, cardiorespiratory fitness; MET, metabolic equivalent; NR, not reported; VO2max, maximal oxygen uptake. 
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case- control studies, Benke and colleagues demonstrated no 
evidence of an association between overall PA and prostate 
cancer incidence.47 Though these null findings may appear 
not to be useful for future research on CRF and prostate can-
cer risk, it does clarify the existing uncertainties regarding 
the association; especially given the body of evidence on 
the strong inverse associations between CRF and some site- 
specific cancers such as lung and colorectal cancers.15,37,45 
Though all- cause and site- specific cancers share some com-
mon risk factors, there are risk factors that are specific to 
some cancers; it is, therefore, expected that the aetiogenesis 
of site- specific cancers may differ. Mechanistic studies are 
needed to delineate the pathways underlying the relationship 
between PA, CRF and the development of specific cancers.
4.1 | Strengths and limitations
The strengths of this evaluation include (a) the large- scale 
population- based prospective cohort design; (b) zero loss 
to follow- up; (c) reliable ascertainment of prostate cancer 
outcomes using a validated national cancer registry; (d) use 
of the gold standard measure for CRF assessment; (e) the 
follow- up period which was sufficiently long to ascertain 
the risk for prostate cancer; (f) ability to correct for within- 
person variability in CRF levels due to availability of repeat 
assessments in a subset of individuals; and (g) comprehen-
sive review of previously published studies on the topic. The 
findings should be interpreted in light of the inability to (a) 
generalise the results to other populations, (b) evaluate the 
impact of CRF on cancer prognosis due to unavailability of 
data on cancer stages, (c) address causality due to the obser-
vational study design; and (d) pool the results of identified 
studies due to wide variation in study methods, exposures 
and outcomes.
5 |  CONCLUSIONS
Primary data based on a cohort of middle- aged Caucasian 
male population and a review of previously published stud-
ies suggest that elevated CRF is not associated with reduced 
prostate cancer risk. The overall findings suggest that previ-
ous results showing evidence of associations could be attrib-
uted to increased screening and detection as well as reverse 
causation bias.
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